Infectious Disease Vaccines

A primary focus of Immunovaccine's partnered programs is protection against infectious diseases including respiratory syncytial virus (RSV) and anthrax.  To date, the company and its collaborators in this area have demonstrated a number of crucial capabilities for the DepoVax™ technology and DepoVax™-based infectious disease vaccines including:

  • Generation of rapid and robust immune responses that are required to achieve infectious disease protection
  • Demonstration of protection in a single dose, a critical requirement for pandemic usage
  • Ability to be combined with a  variety of different antigens including peptides, proteins, VLPs and viral vectors
  • Achievement of stronger and sustained immune response as compared to FDA approved vaccine in anthrax

As part of its work in this area, Immunovaccine is collaborating  with the National Institutes of Health (NIH) on the advancement of four bio-defense candidates in government-funded studies.  To date, one of the most significant breakthroughs in this area involved the demonstration that a single-dose DepoVax-based anthrax vaccine generated higher antibody levels that three doses of an alum-adjuvanted control vaccine.